Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 20/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 20/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PDXK | O00764 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6320000 | 0.99 | FGFR1 (0.42) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL7356094 | 0.91 | FGFR1 (0.47) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL6313429 | 0.84 | NR4A3 (0.56) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL4452229 | 0.83 | NR4A3 (0.39) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL4454489 | 0.83 | NR4A3 (0.39) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL6312652 | 0.83 | FGFR1 (0.45) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| Hydrochloric Acid SCHEMBL6313973 | 0.83 | NR4A3 (0.38) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL4454445 | 0.82 | SLC9A1 (0.44) | FGFR1FGFR2FGFR3SRCFGFR4 | |
| SCHEMBL4460203 | 0.82 | RIPK2 (0.44) | — | |
| Hydrochloric Acid SCHEMBL6321323 | 0.82 | NR4A3 (0.38) | FGFR1FGFR2FGFR3SRCFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1499317-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | Pfizer Products Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| WO-2003092694-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | claimed |
| US-20030212072-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2003-11-13 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | FGFR1 2679/4885FGFR2 4486/4885FGFR3 2835/4885 |
| US-20010056095-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | FGFR1 2299/4885FGFR2 3938/4885FGFR3 4129/4885 |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | NHERF1, SLC5A1, SLC5A2 | FGFR1 1020/4885FGFR2 2213/4885FGFR3 2698/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | FGFR1 1269/4885FGFR2 3639/4885FGFR3 1853/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | FGFR1 2331/4885FGFR2 4231/4885FGFR3 4130/4885 |
| US-20030212072-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | FGFR1 2299/4885FGFR2 3938/4885FGFR3 4129/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | FGFR1 2331/4885FGFR2 4231/4885FGFR3 4130/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | FGFR1 1733/4885FGFR2 4047/4885FGFR3 1647/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | FGFR1 3747/4885FGFR2 4573/4885FGFR3 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.